Dr. Hershman on Adherence to Longer Hormonal Therapy

Dawn L. Hershman, MD
Published: Thursday, Aug 01, 2013

Dawn L. Hershman, MD, MS, Associate Professor of Medicine and Epidemiology, Leader, Breast Cancer Program, Herbert Irving Comprehensive Cancer Center, Columbia University, discusses the need for adherence with longer hormonal therapy.

Recent studies have further verified the benefit for patients with breast cancer to stay on tamoxifen for 10 years as opposed to 5 years. As a result, the oncology community needs to consider issues related to adherence and compliance.

Researchers have found that at the end of 5 years of tamoxifen, only about 50% of patients take the medication greater than 80% of the time. Researchers also saw that about 25-30% of patients discontinued medication completely, while 25% took it intermittently.

These patients are so far out from their diagnosis, Hershman says, so physicians need to think about how to keep these patients engaged in treatment.
 
Dawn L. Hershman, MD, MS, Associate Professor of Medicine and Epidemiology, Leader, Breast Cancer Program, Herbert Irving Comprehensive Cancer Center, Columbia University, discusses the need for adherence with longer hormonal therapy.

Recent studies have further verified the benefit for patients with breast cancer to stay on tamoxifen for 10 years as opposed to 5 years. As a result, the oncology community needs to consider issues related to adherence and compliance.

Researchers have found that at the end of 5 years of tamoxifen, only about 50% of patients take the medication greater than 80% of the time. Researchers also saw that about 25-30% of patients discontinued medication completely, while 25% took it intermittently.

These patients are so far out from their diagnosis, Hershman says, so physicians need to think about how to keep these patients engaged in treatment.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x